Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

Abstract

Dual inhibition of BRAF and downstream MEK may be a safe and effective therapeutic strategy for <i>BRAF</i>-mutant ECD patients for whom BRAF inhibitor therapy proved insufficient and as such appropriate for the long-term management of CNS disease in ECD.